ASCO 2024: Trastuzumab Deruxtecan in Bladder Cancer

By The Uromigos - Last Updated: July 10, 2024

Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial on trastuzumab deruxtecan in patients with HER2-expressing solid tumors.

Post Tags:Uromigos-ASCO
Advertisement

Related Podcasts

Episode 360: The SUNRISE Program in Bladder Cancer
Uromigos-Bladder Cancer
Episode 359: #UromigosLive24 - IO After IO in RCC
Uromigos Live 2024: Focus on Kidney Cancer
Episode 358: Tres Uramigas - News From Day 1 of #UromigosLive24 in Nashville
Uromigos-Bladder Cancer
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
Uromigos Live 2024: Focus on Bladder Cancer
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
Uromigos Live 2024: Focus on Kidney Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy